PE20060240A1 - Derivados de pirimidina para tratar el crecimiento celular anomalo - Google Patents

Derivados de pirimidina para tratar el crecimiento celular anomalo

Info

Publication number
PE20060240A1
PE20060240A1 PE2005000534A PE2005000534A PE20060240A1 PE 20060240 A1 PE20060240 A1 PE 20060240A1 PE 2005000534 A PE2005000534 A PE 2005000534A PE 2005000534 A PE2005000534 A PE 2005000534A PE 20060240 A1 PE20060240 A1 PE 20060240A1
Authority
PE
Peru
Prior art keywords
methyl
ilamino
cycloalkyl
alkyl
cellular growth
Prior art date
Application number
PE2005000534A
Other languages
English (en)
Inventor
John Charles Kath
Michael Joseph Luzzio
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060240(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20060240A1 publication Critical patent/PE20060240A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE n ES 1-3; R1 ES H, HIDROXI, ALQUILO C1-C6, CICLOALQUILO C3-C7, O-ALQUILO C1-C6, ENTRE OTROS; R2 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6, CICLOALQUILO C3-C7, ENTRE OTROS; R3 ES H, ARILO C6-C10 OPCIONALMENTE SUSTITUIDO, CICLOALQUILO C3-C10, HETEROCICLILO C2-C9, ENTRE OTROS; R4 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C7, HETEROCICLILO C2-C9 OPCIONALMENTE SUSTITUIDOS. SON COMPUESTOS PREFERIDOS: N-METIL-N-{3-[({METIL-[2-(2-OXO-2,3-DIHIDRO-1H-INDOL-5-ILAMINO)-5-TRIFLUOROMETIL-PIRIMIDIN-4-IL]-AMINO})-METIL]-FENIL}-METANOSULFONAMIDA; N-METIL-N-(5-METIL-2-{[2-(2-OXO-2,3-DIHIDRO-1H-INDOL-5-ILAMINO)-5-TRIFLUOROMETIL-PIRIMIDIN-4-ILAMINO]-METIL}-FENIL)-METANOSULFONAMIDA; 5-{4-[((1S,2R)-2-HIDROXI-CICLOHEXILMETIL)-AMINO]-5-TRIFLUOROMETIL-PIRIMIDIN-2-ILAMINO}-1,3-DIHIDRO-INDOL-2-ONA; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE QUINASA E INHIBIDORES DE TIROSINA QUINASA NO RECEPTOR, FAK, UTILES EN EL TRATAMIENTO DEL CRECIMIENTO CELULAR ANOMALO
PE2005000534A 2004-05-14 2005-05-12 Derivados de pirimidina para tratar el crecimiento celular anomalo PE20060240A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57131204P 2004-05-14 2004-05-14

Publications (1)

Publication Number Publication Date
PE20060240A1 true PE20060240A1 (es) 2006-04-01

Family

ID=34966230

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000534A PE20060240A1 (es) 2004-05-14 2005-05-12 Derivados de pirimidina para tratar el crecimiento celular anomalo

Country Status (27)

Country Link
EP (1) EP1751143A1 (es)
JP (1) JP4099212B2 (es)
KR (1) KR100886990B1 (es)
CN (2) CN102127058A (es)
AP (1) AP2241A (es)
AR (1) AR049097A1 (es)
AU (2) AU2005243397A1 (es)
BR (1) BRPI0511138A (es)
CA (1) CA2566707A1 (es)
CR (1) CR8749A (es)
EA (1) EA200601796A1 (es)
EC (1) ECSP066997A (es)
GE (1) GEP20104875B (es)
GT (1) GT200500113A (es)
IL (1) IL178828A0 (es)
MA (1) MA28583B1 (es)
MX (1) MXPA06011890A (es)
NL (2) NL1029045C2 (es)
NO (1) NO20064576L (es)
NZ (1) NZ550448A (es)
PA (1) PA8632601A1 (es)
PE (1) PE20060240A1 (es)
TN (1) TNSN06370A1 (es)
TW (1) TWI303635B (es)
UY (1) UY28894A1 (es)
WO (1) WO2005111023A1 (es)
ZA (1) ZA200608394B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2566531A1 (en) * 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
AU2006327871A1 (en) * 2005-12-21 2007-06-28 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
MX2009011090A (es) * 2007-04-18 2009-11-02 Pfizer Prod Inc Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal.
KR20100049068A (ko) * 2007-07-17 2010-05-11 리겔 파마슈티칼스, 인크. Ｐｋｃ 억제제로서의 시클릭 아민 치환된 피리미딘디아민
WO2009071535A1 (en) * 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
CA2723961C (en) * 2008-05-21 2017-03-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
JP5539518B2 (ja) 2009-08-14 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ２−アミノ−５−トリフルオロメチルピリミジン誘導体の位置選択的調製
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
WO2014174745A1 (ja) * 2013-04-26 2014-10-30 国立大学法人京都大学 Ｅｇ５阻害剤
CN109608444B (zh) * 2018-11-27 2022-02-11 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途
CN111732548B (zh) * 2020-06-11 2022-06-17 浙江大学 N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2004056807A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
NL1029045C2 (nl) 2006-06-02
AP2241A (en) 2011-06-01
PA8632601A1 (es) 2006-06-02
EA200601796A1 (ru) 2007-04-27
NL1031845A1 (nl) 2006-07-31
ECSP066997A (es) 2007-02-28
CA2566707A1 (en) 2005-11-24
GT200500113A (es) 2006-01-10
UY28894A1 (es) 2005-12-30
JP2007537234A (ja) 2007-12-20
KR100886990B1 (ko) 2009-03-04
JP4099212B2 (ja) 2008-06-11
GEP20104875B (en) 2010-01-11
NO20064576L (no) 2006-11-07
MXPA06011890A (es) 2006-12-14
ZA200608394B (en) 2008-05-28
AP2006003790A0 (en) 2006-10-31
NZ550448A (en) 2010-11-26
MA28583B1 (fr) 2007-05-02
AR049097A1 (es) 2006-06-28
NL1029045A1 (nl) 2005-11-15
CR8749A (es) 2006-12-05
TWI303635B (en) 2008-12-01
NL1031845C2 (nl) 2006-11-23
CN1953974A (zh) 2007-04-25
CN102127058A (zh) 2011-07-20
TNSN06370A1 (fr) 2008-02-22
AU2005243397A1 (en) 2005-11-24
KR20070012477A (ko) 2007-01-25
WO2005111023A1 (en) 2005-11-24
BRPI0511138A (pt) 2007-11-27
TW200539871A (en) 2005-12-16
AU2009238255A1 (en) 2009-12-03
EP1751143A1 (en) 2007-02-14
IL178828A0 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
PE20060240A1 (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
PE20090813A1 (es) Inhibidores de la 11b-hidroxiesteroide-deshidrogenasa
PE20191755A1 (es) Derivados de pirazol como inhibidores de malt 1
PE20090772A1 (es) Derivados de bencimidazol
PE20110367A1 (es) DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
PE20090890A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c
PE20081393A1 (es) Derivados de quinolina como inhibidores de csf-1r
PE20080538A1 (es) Derivado heterociclico fusionado y su uso
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
PE20071223A1 (es) Procedimiento de preparacion de derivados de acil-amino-alquilen-amida
EA201171333A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
AR037996A1 (es) Compuesto derivado de amino nicotinato, composicion farmaceutica; proceso para su preparacion y su uso como medicamento
PE20041016A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PE20090649A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20110308A1 (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
PE20081545A1 (es) Derivados de sulfonamida como inhibidores de acido graso sintasas
PE20090641A1 (es) Amidas heterociclicas
PE20091527A1 (es) Derivados de piridazinona
PE20090210A1 (es) Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa
EA201400111A1 (ru) Ингибиторы mek и способы их применения
PE20091486A1 (es) Derivado de pirrolopirimidina como inhibidor de la enzima pi3k
PE20081796A1 (es) Derivados de pirimidina

Legal Events

Date Code Title Description
FC Refusal